Literature DB >> 11242109

X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling.

R Döffinger1, A Smahi, C Bessia, F Geissmann, J Feinberg, A Durandy, C Bodemer, S Kenwrick, S Dupuis-Girod, S Blanche, P Wood, S H Rabia, D J Headon, P A Overbeek, F Le Deist, S M Holland, K Belani, D S Kumararatne, A Fischer, R Shapiro, M E Conley, E Reimund, H Kalhoff, M Abinun, A Munnich, A Israël, G Courtois, J L Casanova.   

Abstract

The molecular basis of X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) has remained elusive. Here we report hypomorphic mutations in the gene IKBKG in 12 males with EDA-ID from 8 kindreds, and 2 patients with a related and hitherto unrecognized syndrome of EDA-ID with osteopetrosis and lymphoedema (OL-EDA-ID). Mutations in the coding region of IKBKG are associated with EDA-ID, and stop codon mutations, with OL-EDA-ID. IKBKG encodes NEMO, the regulatory subunit of the IKK (IkappaB kinase) complex, which is essential for NF-kappaB signaling. Germline loss-of-function mutations in IKBKG are lethal in male fetuses. We show that IKBKG mutations causing OL-EDA-ID and EDA-ID impair but do not abolish NF-kappaB signaling. We also show that the ectodysplasin receptor, DL, triggers NF-kappaB through the NEMO protein, indicating that EDA results from impaired NF-kappaB signaling. Finally, we show that abnormal immunity in OL-EDA-ID patients results from impaired cell responses to lipopolysaccharide, interleukin (IL)-1beta, IL-18, TNFalpha and CD154. We thus report for the first time that impaired but not abolished NF-kappaB signaling in humans results in two related syndromes that associate specific developmental and immunological defects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11242109     DOI: 10.1038/85837

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  224 in total

Review 1.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

3.  Finding NEMO: genetic disorders of NF-[kappa]B activation.

Authors:  Jordan S Orange; Raif S Geha
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 4.  NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions.

Authors:  Jorge Caamaño; Christopher A Hunter
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

Review 5.  NF-kappaB in critical diseases: a bad guy?

Authors:  Uwe Senftleben
Journal:  Intensive Care Med       Date:  2003-09-04       Impact factor: 17.440

6.  Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4.

Authors:  John M Darlow; Alex M Farrell; David I Stott
Journal:  Immunology       Date:  2004-02       Impact factor: 7.397

Review 7.  Nuclear factor (NF)-kappaB proteins: therapeutic targets.

Authors:  I M Verma
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 8.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

Review 9.  "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappaB activation.

Authors:  Jérémie Gautheron; Gilles Courtois
Journal:  Cell Mol Life Sci       Date:  2010-05-26       Impact factor: 9.261

10.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.